mRNA as a versatile tool for exogenous protein expression

Current Gene Therapy

Volumn 12, Issue 5, 2012, Pages 347-361

  Kuhn, Andreas N ^a,b   Beißert, Tim ^a   Simon, Petra ^a   Vallazza, Britta ^b   Buck, Janina ^b   Davies, Brian P ^a,b   Türeci, Özlem ^a   Sahin, Ugur ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Ribological GmbH   (Germany)

Author keywords

Gene therapy; Genetic modifications; Immunotherapy; In vitro transcription; mRNA; RNA stability; Stem cells; T cell therapy; Transfection; Translation

Indexed keywords

DNA; MESSENGER RNA; RECOMBINANT DNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; DNA MODIFICATION; DNA VECTOR; GENE THERAPY; HUMAN; INNATE IMMUNITY; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REVIEW; RNA SEQUENCE; RNA STABILITY; RNA TRANSLATION; RNA TRANSPORT; RNA VECTOR; T LYMPHOCYTE;

ANIMALS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA STABILITY; RNA, MESSENGER;

EID: 84866979353     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802762536     Document Type: Review

References (184)

1. Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010; 17(8): 961-71.
2. Escoffre JM, Portet T, Wasungu L, Teissie J, Dean D, Rols MP. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol Biotechnol 2009; 41(3): 286-95.
3. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther 2010; 17(4): 439-47.
4. Yisraeli JK, Melton DA. Synthesis of long, capped transcripts in vitro by SP6 and T7 RNA polymerases. Methods Enzymol 1989; 180: 42-50.
5. Nagata S, Hamasaki T, Uetake K, Masuda H, Takagaki K, Oka N, et al. Synthesis and biological activity of artificial mRNA prepared with novel phosphorylating reagents. Nucleic Acids Res 2010; 38(21): 7845-57.
6. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108(13): 4009-17.
7. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004; 4(8): 1285-94.
8. Tavernier G, Andries O, Demeester J, Sanders NN, De Smedt SC, Rejman J. mRNA as gene therapeutic: how to control protein expression. J Control Release 2011; 150(3): 238-47.
9. Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011; 39(21): e142.
10. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7(5): 618-30.
11. Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010; 394(1): 189-93.
12. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van BC, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98(1): 49-56.
13. Plews JR, Li J, Jones M, Moore HD, Mason C, Andrews PW, et al. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS One 2010; 5(12): e14397.
14. Galla M, Schambach A, Towers GJ, Baum C. Cellular restriction of retrovirus particle-mediated mRNA transfer. J Virol 2008; 82(6): 3069-77.
15. Galla M, Will E, Kraunus J, Chen L, Baum C. Retroviral pseudotransduction for targeted cell manipulation. Mol Cell 2004; 16(2): 309-15.
16. Galla M, Schambach A, Falk CS, Maetzig T, Kuehle J, Lange K, et al. Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 2011; 39(16): 7147-60.
17. Nash KL, Lever AM. Green fluorescent protein: green cells do not always indicate gene expression. Gene Ther 2004; 11(11): 882-3.
18. Munch RC, Muhlebach MD, Schaser T, Kneissl S, Jost C, Pluckthun A, et al. DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 2011; 19(4): 686-93.
19. Buchholz CJ, Muhlebach MD, Cichutek K. Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol 2009; 27(5): 259-65.
20. Beumer KJ, Trautman JK, Bozas A, Liu JL, Rutter J, Gall JG, et al. Efficient gene targeting in Drosophila by direct embryo injection with zinc-finger nucleases. Proc Natl Acad Sci U S A 2008; 105(50): 19821-6.
21. Takasu Y, Kobayashi I, Beumer K, Uchino K, Sezutsu H, Sajwan S, et al. Targeted mutagenesis in the silkworm Bombyx mori using zinc finger nuclease mRNA injection. Insect Biochem Mol Biol 2010; 40(10): 759-65.
22. Tesson L, Usal C, Menoret S, Leung E, Niles BJ, Remy S, et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011; 29(8): 695-6.
23. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4): 783-801.
24. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007; 141(2): 137-45.
25. Yoneyama M, Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 2008; 29(2): 178-81.
26. Wilkins C, Gale M, Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010; 22(1): 41-7.
27. Nallagatla SR, Toroney R, Bevilacqua PC. Regulation of innate immunity through RNA structure and the protein kinase PKR. Curr Opin Struct Biol 2011; 21(1): 119-27.
28. Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, et al. The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res 2011; 39(Database issue): D195-D201.
29. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010; 38(17): 5884-92.
30. Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Kariko K. Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 2011; 39(21): 9329-38.
31. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011; 29(2): 154-7.
32. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314(5801): 994-7.
33. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006; 314(5801): 997-1001.
34. Angel M, Yanik MF. Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. PLoS One 2010; 5(7): e11756.
35. Balagopal V, Fluch L, Nissan T. Ways and means of eukaryotic mRNA decay. Biochim Biophys Acta 2012; 1819(6): 593-603.
36. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007; 8(2): 113-26.
37. Houseley J, Tollervey D. The many pathways of RNA degradation. Cell 2009; 136(4): 763-76.
38. Lykke-Andersen S, Tomecki R, Jensen TH, Dziembowski A. The eukaryotic RNA exosome: same scaffold but variable catalytic subunits. RNA Biol 2011; 8(1): 61-6.
39. Liu SW, Rajagopal V, Patel SS, Kiledjian M. Mechanistic and kinetic analysis of the DcpS scavenger decapping enzyme. J Biol Chem 2008; 283(24): 16427-36.
40. Song MG, Li Y, Kiledjian M. Multiple mRNA decapping enzymes in mammalian cells. Mol Cell 2010; 40(3): 423-32.
41. Jinek M, Coyle SM, Doudna JA. Coupled 5' nucleotide recognition and processivity in Xrn1-mediated mRNA decay. Mol Cell 2011; 41(5): 600-8.
42. Chang JH, Xiang S, Xiang K, Manley JL, Tong L. Structural and biochemical studies of the 5'-3' exoribonuclease Xrn1. Nat Struct Mol Biol 2011; 18(3): 270-6.
43. Hsu CL, Stevens A. Yeast cells lacking 5'-3' exoribonuclease 1 contain mRNA species that are poly(A) deficient and partially lack the 5' cap structure. Mol Cell Biol 1993; 13(8): 4826-35.
44. Kulkarni M, Ozgur S, Stoecklin G. On track with P-bodies. Biochem Soc Trans 2010; 38(Pt 1): 242-51.
45. Tomecki R, Dziembowski A. Novel endoribonucleases as central players in various pathways of eukaryotic RNA metabolism. RNA 2010; 16(9): 1692-724.
46. Li WM, Barnes T, Lee CH. Endoribonucleases--enzymes gaining spotlight in mRNA metabolism. FEBS J 2010; 277(3): 627-41.
47. Wilusz J. RNA stability: is it the endo' the world as we know it? Nat Struct Mol Biol 2009; 16(1): 9-10.
48. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008; (183): 221-35.
49. Pasquinelli AE, Dahlberg JE, Lund E. Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA 1995; 1(9): 957-67.
50. Jemielity J, Fowler T, Zuberek J, Stepinski J, Lewdorowicz M, Niedzwiecka A, et al. Novel anti-reverse cap analogs with superior translational properties. RNA 2003; 9(9): 1108-22.
51. Peng ZH, Sharma V, Singleton SF, Gershon PD. Synthesis and application of a chain-terminating dinucleotide mRNA cap analog. Org Lett 2002; 4(2): 161-4.
52. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel antireverse cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA 2001; 7(10): 1486-95.
53. Mockey M, Goncalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006; 340(4): 1062-8.
54. Bontkes HJ, Kramer D, Ruizendaal JJ, Kueter EW, Van Tendeloo VF, Meijer CJ, et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 2007; 14(4): 366-75.
55. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, et al. Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 2006; 17(10): 1027-35.
56. Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Polcher M, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007; 8(5): 451-4.
57. Kore AR, Shanmugasundaram M, Charles I, Cheng AM, Barta TJ. Synthesis and application of 2'-fluoro-substituted cap analogs. Bioorg Med Chem Lett 2007; 17(19): 5295-9.
58. Kore AR, Shanmugasundaram M, Vlassov AV. Synthesis and application of a new 2',3'-isopropylidene guanosine substituted cap analog. Bioorg Med Chem Lett 2008; 18(17): 4828-32.
59. Kore AR, Shanmugasundaram M, Charles I, Vlassov AV, Barta TJ. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization. J Am Chem Soc 2009; 131(18): 6364-5.
60. Kore AR, Charles I. Synthesis and evaluation of 2'-O-allyl substituted dinucleotide cap analog for mRNA translation. Bioorg Med Chem 2010; 18(22): 8061-5.
61. Grudzien E, Stepinski J, Jankowska-Anyszka M, Stolarski R, Darzynkiewicz E, Rhoads RE. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004; 10(9): 1479-87.
62. Kalek M, Jemielity J, Darzynkiewicz ZM, Bojarska E, Stepinski J, Stolarski R, et al. Enzymatically stable 5' mRNA cap analogs: synthesis and binding studies with human DcpS decapping enzyme. Bioorg Med Chem 2006; 14(9): 3223-30.
63. Grudzien E, Kalek M, Jemielity J, Darzynkiewicz E, Rhoads RE. Differential inhibition of mRNA degradation pathways by novel cap analogs. J Biol Chem 2006; 281(4): 1857-67.
64. Su W, Slepenkov S, Grudzien-Nogalska E, Kowalska J, Kulis M, Zuberek J, et al. Translation, stability, and resistance to decapping of mRNAs containing caps substituted in the triphosphate chain with BH3, Se, and NH. RNA 2011; 17(5): 978-88.
65. Rydzik AM, Kulis M, Lukaszewicz M, Kowalska J, Zuberek J, Darzynkiewicz ZM, et al. Synthesis and properties of mRNA cap analogs containing imidodiphosphate moiety--fairly mimicking natural cap structure, yet resistant to enzymatic hydrolysis. Bioorg Med Chem 2012; 20(5): 1699-710.
66. Kowalska J, Lewdorowicz M, Zuberek J, Grudzien-Nogalska E, Bojarska E, Stepinski J, et al. Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS. RNA 2008; 14(6): 1119-31.
67. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007; 13(10): 1745-55.
68. Van DE, Cougot N, Meyer S, Babajko S, Wahle E, Seraphin B. Human Dcp2: a catalytically active mRNA decapping enzyme located in specific cytoplasmic structures. EMBO J 2002; 21(24): 6915-24.
69. Kowalska J, Lukaszewicz M, Zuberek J, Darzynkiewicz E, Jemielity J. Phosphoroselenoate dinucleotides for modification of mRNA 5' end. Chembiochem 2009; 10(15): 2469-73.
70. Jemielity J, Fowler T, Zuberek J, Stepinski J, Lewdorowicz M, Niedzwiecka A, et al. Novel anti-reverse cap analogs with superior translational properties. RNA 2003; 9(9): 1108-22.
71. Zdanowicz A, Thermann R, Kowalska J, Jemielity J, Duncan K, Preiss T, et al. Drosophila miR2 primarily targets the m7GpppN cap structure for translational repression. Mol Cell 2009; 35(6): 881-8.
72. Rydzik AM, Lukaszewicz M, Zuberek J, Kowalska J, Darzynkiewicz ZM, Darzynkiewicz E, et al. Synthetic dinucleotide mRNA cap analogs with tetraphosphate 5',5' bridge containing methylenebis(phosphonate) modification. Org Biomol Chem 2009; 7(22): 4763-76.
73. Strenkowska M, Kowalska J, Lukaszewicz M, Zuberek J, Su W, Rhoads RE, et al. Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications. New J Chem 2010; 34(5): 993-1007.
74. Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 2008; 9: 90.
75. Martinez-Salas E, Pacheco A, Serrano P, Fernandez N. New insights into internal ribosome entry site elements relevant for viral gene expression. J Gen Virol 2008; 89(Pt 3): 611-26.
76. Tan X, Wan Y. Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Hum Immunol 2008; 69(1): 32-40.
77. Waggoner SA, Liebhaber SA. Identification of mRNAs associated with alphaCP2-containing RNP complexes. Mol Cell Biol 2003; 23(19): 7055-67.
78. Yu J, Russell JE. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol 2001; 21(17): 5879-88.
79. Holcik M, Liebhaber SA. Four highly stable eukaryotic mRNAs assemble 3' untranslated region RNA-protein complexes sharing cis and trans components. Proc Natl Acad Sci U S A 1997; 94(6): 2410-4.
80. Jiang Y, Xu XS, Russell JE. A nucleolin-binding 3' untranslated region element stabilizes beta-globin mRNA in vivo. Mol Cell Biol 2006; 26(6): 2419-29.
81. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, et al. Efficient presentation of known HLA class IIrestricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 2003; 63(17): 5587-94.
82. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A 1989; 86(16): 6077-81.
83. Bergman N, Moraes KC, Anderson JR, Zaric B, Kambach C, Schneider RJ, et al. Lsm proteins bind and stabilize RNAs containing 5' poly(A) tracts. Nat Struct Mol Biol 2007; 14(9): 824-31.
84. Frolov I, Schlesinger S. Translation of Sindbis virus mRNA: analysis of sequences downstream of the initiating AUG codon that enhance translation. J Virol 1996; 70(2): 1182-90.
85. Sjoberg EM, Suomalainen M, Garoff H. A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology (NY) 1994; 12(11): 1127-31.
86. Pogue GP, Cao XQ, Singh NK, Nakhasi HL. 5' sequences of rubella virus RNA stimulate translation of chimeric RNAs and specifically interact with two host-encoded proteins. J Virol 1993; 67(12): 7106-17.
87. Garneau NL, Sokoloski KJ, Opyrchal M, Neff CP, Wilusz CJ, Wilusz J. The 3' untranslated region of sindbis virus represses deadenylation of viral transcripts in mosquito and Mammalian cells. J Virol 2008; 82(2): 880-92.
88. Hayashi T, Lamba DA, Slowik A, Reh TA, Bermingham-McDonogh O. A method for stabilizing RNA for transfection that allows control of expression duration. Dev Dyn 2010; 239(7): 2034-40.
89. Chiu WW, Kinney RM, Dreher TW. Control of translation by the 5'-and 3'-terminal regions of the dengue virus genome. J Virol 2005; 79(13): 8303-15.
90. Holden KL, Harris E. Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. Virology 2004; 329(1): 119-33.
91. Garfinkel MS, Katze MG. Translational control by influenza virus. Selective translation is mediated by sequences within the viral mRNA 5'-untranslated region. J Biol Chem 1993; 268(30): 22223-6.
92. Sjoberg EM, Garoff H. The translation-enhancing region of the Semliki Forest virus subgenome is only functional in the virusinfected cell. J Gen Virol 1996; 77 (Pt 6): 1323-7.
93. Zinckgraf JW, Silbart LK. Modulating gene expression using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 2003; 21(15): 1640-9.
94. Grantham R, Gautier C, Gouy M, Mercier R, Pave A. Codon catalog usage and the genome hypothesis. Nucleic Acids Res 1980; 8(1): r49-r62.
95. Ikemura T. Codon usage and tRNA content in unicellular and multicellular organisms. Mol Biol Evol 1985; 2(1): 13-34.
96. Bossi L, Ruth JR. The influence of codon context on genetic code translation. Nature 1980; 286(5769): 123-7.
97. Gustafsson C, Minshull J, Govindarajan S, Ness J, Villalobos A, Welch M. Engineering genes for predictable protein expression. Protein Expr Purif 2012; 83(1): 37-46.
98. Moura GR, Pinheiro M, Freitas A, Oliveira JL, Frommlet JC, Carreto L, et al. Species-specific codon context rules unveil nonneutrality effects of synonymous mutations. PLoS One 2011; 6(10): e26817.
99. Tats A, Tenson T, Remm M. Preferred and avoided codon pairs in three domains of life. BMC Genomics 2008; 9: 463.
100. Duan J, Antezana MA. Mammalian mutation pressure, synonymous codon choice, and mRNA degradation. J Mol Evol 2003; 57(6): 694-701.
101. Khabar KS. The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005; 25(1): 1-10.
102. Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One 2011; 6(3): e17596.
103. Van den Bosch GA, Van GE, Ponsaerts P, Nijs G, Lenjou M, Apers L, et al. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother 2006; 29(5): 512-23.
104. Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De RA, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107(5): 1818-27.
105. Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jager E, Tiercy JM, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother 2009; 58(3): 325-38.
106. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119(2): 135-45.
107. Bernstein P, Peltz SW, Ross J. The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro. Mol Cell Biol 1989; 9(2): 659-70.
108. Sachs AB, Davis RW, Kornberg RD. A single domain of yeast poly(A)-binding protein is necessary and sufficient for RNA binding and cell viability. Mol Cell Biol 1987; 7(9): 3268-76.
109. Baer BW, Kornberg RD. Repeating structure of cytoplasmic poly(A)-ribonucleoprotein. Proc Natl Acad Sci U S A 1980; 77(4): 1890-2.
110. Wells SE, Hillner PE, Vale RD, Sachs AB. Circularization of mRNA by eukaryotic translation initiation factors. Mol Cell 1998; 2(1): 135-40.
111. Martin G, Keller W. Tailing and 3'-end labeling of RNA with yeast poly(A) polymerase and various nucleotides. RNA 1998; 4(2): 226-30.
112. Korner CG, Wahle E. Poly(A) tail shortening by a mammalian poly(A)-specific 3'-exoribonuclease. J Biol Chem 1997; 272(16): 10448-56.
113. Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C, Tureci O. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res 2007; 67(19): 9528-34.
114. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De PE, van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254(5038): 1643-7.
115. Bei R, Scardino A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J Biomed Biotechnol 2010; 2010: 102758.
116. Chen X, Chang CH, Goldenberg DM. Novel strategies for improved cancer vaccines. Expert Rev Vaccines 2009; 8(5): 567-76.
117. Humbert JM, Halary F. Viral and non-viral methods to genetically modify dendritic cells. Curr Gene Ther 2012; 12(2): 127-36.
118. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12(4): 265-77.
119. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA-and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115(1): 33-42.
120. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA transfected dendritic cells. Immunol Rev 2004; 199: 251-63.
121. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009; 15(7): 2531-40.
122. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13(10): 905-18.
123. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93(7): 749-56.
124. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59(14): 3340-5.
125. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247(4949 Pt 1): 1465-8.
126. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70(22): 9031-40.
127. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003; 18(3): 343-54.
128. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121(2): 216-26.
129. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005; 35(5): 1557-66.
130. Espuelas S, Roth A, Thumann C, Frisch B, Schuber F. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol Immunol 2005; 42(6): 721-9.
131. Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995; 55(7): 1397-400.
132. Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 2007; 14(15): 1175-80.
133. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Tureci O, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011; 18(7): 702-8.
134. Van LS, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72(7): 1661-71.
135. Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine 2008; 26(50): 6433-40.
136. Naka T, Iwahashi M, Nakamura M, Ojima T, Nakamori M, Ueda K, et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Sci 2008; 99(2): 407-13.
137. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184(2): 465-72.
138. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostatespecific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109(3): 409-17.
139. Kreiter S, Diken M, Selmi A, Tureci O, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 2011; 23(3): 399-406.
140. Bringmann A, Held SA, Heine A, Brossart P. RNA vaccines in cancer treatment. J Biomed Biotechnol 2010; 2010: 623-687.
141. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10(9): 909-15.
142. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31(2): 180-8.
143. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19(5): 990-9.
144. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32(5): 498-507.
145. Vera JF, Brenner MK, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther 2009; 9(5): 396-408.
146. Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 2011; 11(4): 276-87.
147. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2(7): 512-9.
148. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010; 10(2): 77-90.
149. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163(1): 507-13.
150. Kessels HW, Wolkers MC, Van B, Van V, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001; 2(10): 957-61.
151. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314(5796): 126-9.
152. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114(3): 535-46.
153. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19(3): 620-6.
154. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J Clin Oncol 2011.
155. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112(6): 2261-71.
156. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3(95): 95ra73.
157. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29(11): 550-7.
158. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009; 9(10): 704-16.
159. Schambach A, Baum C. Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther 2008; 8(6): 474-82.
160. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4(132): 132ra53.
161. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18(4): 843-51.
162. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006; 13(1): 151-9.
163. Schaft N, Dorrie J, Muller I, Beck V, Baumann S, Schunder T, et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 2006; 55(9): 1132-41.
164. Yoon SH, Lee JM, Cho HI, Kim H, Kim HS, Park MY, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft. Cancer Gene Ther 2009; 16: 489-97.
165. Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman JL, Budak-Alpdogan T, Karpikov A, et al. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther 2009; 20(1): 51-61.
166. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70(22): 9053-61.
167. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 22(12): 1575-86.
168. Lee JM, Yoon SH, Kim HS, Kim SY, Sohn HJ, Oh ST, et al. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. Cancer Gene Ther 2010; 17(10): 742-50.
169. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012; 11(3): 517-25.
170. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.
171. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481(7381): 295-305.
172. Okita K, Ichisaka T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature 2007; 448(7151): 313-7.
173. Tavernier G, Wolfrum K, Demeester J, De Smedt SC, Adjaye J, Rejman J. Activation of pluripotency-associated genes in mouse embryonic fibroblasts by non-viral transfection with in vitroderived mRNAs encoding Oct4, Sox2, Klf4 and cMyc. Biomaterials 2012; 33(2): 412-7.
174. Szabo E, Rampalli S, Risueno RM, Schnerch A, Mitchell R, Fiebig-Comyn A, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010; 468(7323): 521-6.
175. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463(7284): 1035-41.
176. Carroll D. Zinc-finger nucleases: a panoramic view. Curr Gene Ther 2011; 11(1): 2-10.
177. Handel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther 2011; 11(1): 28-37.
178. Mussolino C, Cathomen T. TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol 2012.
179. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 2008; 26(6): 702-8.
180. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009; 325(5939): 433.
181. Li X, Heinrich JC, Scott MJ. piggyBac-mediated transposition in Drosophila melanogaster: an evaluation of the use of constitutive promoters to control transposase gene expression. Insect Mol Biol 2001; 10(5): 447-55.
182. Wilber A, Wangensteen KJ, Chen Y, Zhuo L, Frandsen JL, Bell JB, et al. Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther 2007; 15(7): 1280-7.
183. Wilber A, Frandsen JL, Geurts JL, Largaespada DA, Hackett PB, McIvor RS. RNA as a source of transposase for Sleeping Beautymediated gene insertion and expression in somatic cells and tissues. Mol Ther 2006; 13(3): 625-30.
184. Kariko K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 2012; 20(5): 948-53.